RSS
X-linked hypophosphatemia (XLH)
EC grants conditional marketing authorisation for Crysvita
The European Commission (EC) has revealed its decision to grant conditional marketing authorisation to Kyowa Kirin for Crysvita (burosumab) to treat X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children & adolescents more
